ATE79761T1 - Behandlung einer krankheit vom aids-typ. - Google Patents

Behandlung einer krankheit vom aids-typ.

Info

Publication number
ATE79761T1
ATE79761T1 AT87900438T AT87900438T ATE79761T1 AT E79761 T1 ATE79761 T1 AT E79761T1 AT 87900438 T AT87900438 T AT 87900438T AT 87900438 T AT87900438 T AT 87900438T AT E79761 T1 ATE79761 T1 AT E79761T1
Authority
AT
Austria
Prior art keywords
pct
aids
treatment
type disease
sec
Prior art date
Application number
AT87900438T
Other languages
English (en)
Inventor
Robert E Donahue
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25184024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79761(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE79761T1 publication Critical patent/ATE79761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT87900438T 1985-11-27 1986-11-25 Behandlung einer krankheit vom aids-typ. ATE79761T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80255385A 1985-11-27 1985-11-27
EP87900438A EP0246322B1 (de) 1985-11-27 1986-11-25 Behandlung einer krankheit vom aids-typ
PCT/US1986/002575 WO1987003204A1 (en) 1985-11-27 1986-11-25 Treatment of aids-type disease

Publications (1)

Publication Number Publication Date
ATE79761T1 true ATE79761T1 (de) 1992-09-15

Family

ID=25184024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87900438T ATE79761T1 (de) 1985-11-27 1986-11-25 Behandlung einer krankheit vom aids-typ.

Country Status (7)

Country Link
US (1) US4921837A (de)
EP (1) EP0246322B1 (de)
JP (1) JPH0764742B2 (de)
AT (1) ATE79761T1 (de)
AU (1) AU589731B2 (de)
DE (1) DE3686582T2 (de)
WO (1) WO1987003204A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156300A (en) * 1985-02-05 2000-12-05 Chiron Corporation Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US6146851A (en) * 1985-02-05 2000-11-14 Chiron Corporation DNA encoding NV2 (long form) and carboxy truncated fragments thereof
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1986004607A1 (en) * 1985-02-05 1986-08-14 Cetus Corporation Recombinant colony stimulating factor-1
AU625807B2 (en) * 1987-09-22 1992-07-16 Novartis Vaccines And Diagnostics, Inc. Uses of recombinant colony stimulating factor-1
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
IL92234A (en) * 1988-11-09 1993-06-10 Schering Corp Pharmaceutical compositions containing ganciclovir and granulocyte macrophage colony stimulating factor for treatment of myelosuppression associated with acquired immune deficiency
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
DK0382381T3 (da) * 1989-01-30 1993-07-12 Schering Corp Behandling af leukocyt-dysfunktion med GM-CSF
US5087453A (en) * 1990-11-01 1992-02-11 Otsuka Pharmaceutical Co., Ltd. Method for the treatment of bacterial caused weight loss and/or hypoglycemia
US5204101A (en) * 1991-10-15 1993-04-20 Stubblefield Thomas W Method and composition for treating acquired immunodeficiency syndrome
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
EP1124418A4 (de) * 1998-11-06 2004-05-26 Schering Ag Verwendung von gm-csf zur hemmung der medikamentenresistenz-entwicklung bei hiv-positiven patienten
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE451844B (sv) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd Glykoprotein, forfarande for framstellning derav samt terapeutiskt medel innehallande nemnda glykoprotein
US4230697A (en) * 1978-07-03 1980-10-28 Morinaga Milk Industry Co. Ltd. Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same
JPS57149228A (en) * 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
WO1986004587A1 (en) * 1985-02-05 1986-08-14 Cetus Corporation Purification of native colony stimulating factor-1
CA1297003C (en) * 1985-09-20 1992-03-10 Jack H. Nunberg Composition and method for treating animals
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤

Also Published As

Publication number Publication date
US4921837A (en) 1990-05-01
WO1987003204A1 (en) 1987-06-04
EP0246322A4 (de) 1989-11-07
AU6739787A (en) 1987-07-01
EP0246322B1 (de) 1992-08-26
JPH0764742B2 (ja) 1995-07-12
EP0246322A1 (de) 1987-11-25
JPS63502342A (ja) 1988-09-08
AU589731B2 (en) 1989-10-19
DE3686582T2 (de) 1993-01-28
DE3686582D1 (de) 1992-10-01

Similar Documents

Publication Publication Date Title
ATE79761T1 (de) Behandlung einer krankheit vom aids-typ.
DE69024039D1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
ATE62414T1 (de) Mittel zur behandlung von herzerkrankungen.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
ATE104380T1 (de) Sauerstoffdelignifizierung und enzymatische behandlung.
ATE79544T1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
SE7903186L (sv) Cerebralverksamt medel
DE3669997D1 (de) Rollstuhl und anwendungsweise.
DE3750934D1 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
DE3774918D1 (de) Cancerostatisches mittel.
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
DE3670310D1 (de) Elektrochemische behandlung von ligninen.
DE3777861D1 (de) Behandlung von gasen.
DE3684755D1 (de) Behandlung von tieren mit il-2, zubereitungen dafuer und ihre herstellung.
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
IT1207504B (it) Composizione moderatrice dell'appetito ed antigastrica.
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
ATE39694T1 (de) (pyrrol-1-yl)-phenyl-dihydropyridazinone, ihre herstellung und verwendung.
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
DE3582935D1 (de) Mittel zur behandlung von erkrankungen der venen und des analbereichs.
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
ATE10361T1 (de) Derivate von 3-phenoxy-2-propanolen, ihre herstellung und ihre therapeutische verwendung.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
ATE75399T1 (de) Therapeutikum zur behandlung von magengeschwueren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties